QI
NBIX icon

Qtron Investments’s Neurocrine Biosciences NBIX Stock Holding History

Qtron Investments’s Portfolio NBIX Stock Details NBIX Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2024
Q3 		– Sell
-2,815
Closed -$388K – 463
2024
Q2 		$388K Hold
2,815
– – 0.06% 356
2024
Q1 		$388K Sell
2,815
-1,256
-31% -$172K 0.06% 391
2023
Q4 		$536K Hold
4,071
– – 0.09% 314
2023
Q3 		$458K Sell
4,071
-660
-14% -$69.5K 0.09% 305
2023
Q2 		$446K Hold
4,731
– – 0.08% 298
2023
Q1 		$479K Hold
4,731
– – 0.1% 279
2022
Q4 		$565K Buy
4,731
+2,815
+147% +$330K 0.12% 240
2022
Q3 		$203K Buy
+1,916
New +$194K 0.05% 394

Other funds holding NBIX

BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
Renaissance Technologies
Renaissance Technologies New York $63.9B AUM 45.56% 1-Year Est. Return
BG
Bellevue Group Kuesnacht, Switzerland $4.2B AUM 54.85% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return
AQR Capital Management
AQR Capital Management Greenwich, Connecticut $218B AUM 29.41% 1-Year Est. Return
Citadel Advisors
Citadel Advisors Miami, Florida $618B AUM 30.34% 1-Year Est. Return
T. Rowe Price Associates
T. Rowe Price Associates Baltimore, Maryland $865B AUM 30.76% 1-Year Est. Return
JP Morgan Chase
JP Morgan Chase New York $1.56T AUM 27.86% 1-Year Est. Return

Qtron Investments's NBIX Position: Q3 2024 in Review

Qtron Investments sold out of Neurocrine Biosciences (NBIX) in Q3 2024, closing a stake of 2,815 shares — an estimated $388K sold.

Qtron Investments first reported a position in NBIX in Q3 2022 and held it in 8 quarters. The position peaked at $565K in Q4 2022. 574 funds tracked by Wall St. Rank hold NBIX as of Q3 2024.

  • Qtron Investments reported no remaining Neurocrine Biosciences position as of Q3 2024 after selling out during the quarter.
  • Qtron Investments sold 2,815 Neurocrine Biosciences shares in Q3 2024, an estimated $388K.
  • Qtron Investments first reported a position in Neurocrine Biosciences in Q3 2022 and held it in 8 quarters.
  • Qtron Investments's Neurocrine Biosciences position peaked at $565K in Q4 2022.
  • 574 funds tracked by Wall St. Rank held Neurocrine Biosciences as of Q3 2024.

Based on Qtron Investments's 13F filing for Q3 2024, filed 13 Nov 2024.